Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
"Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis"
The SUSTAIN clinical trial programme has documented Semaglutides superior glycaemic and weight-reducing efficacy relative to placebo, sitagliptin, exenatide extended-release, insulin glargine, and dulaglutide establishing Semaglutide as the highest-efficacy selective GLP-1R agonist in comparative clinical pharmacology and providing the translational reference dataset for pre-clinical mechanistic research into the molecular basis of its superior outcomes
We monitor for these during treatment
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed this issue and found no proven causal link with suicidal ideation, though monitoring continues
Hasegawa, K., Sakamaki, Y., Tamaki, M
Science 321 , 569572 (2008)
